Predictors of Pulmonary Hypertension Risk in Premature Infants With Bronchopulmonary Dysplasia
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A lung condition called bronchopulmonary dysplasia (BPD) is a major cause of poor outcomes and death for premature infants. Infants with BPD are also at high risk for pulmonary hypertension (PH)—an important contributor to their condition. Previous research has suggested that a protein in the blood, endothelin-1 (ET-1), is associated with pulmonary disease.
This study aims to investigate the incidence of incidence of PH and levels of ET-1 among premature babies with BPD. It will also potentially allow us to focus further research efforts and treatment towards these infants, some of our sickest patients at LPCH.This study aims to 1) investigate the incidence of PH among premature infants with BPD versus those without BPD; 2) investigate ET-1 levels in infants with BPD-associated PH versus those without BPD-associated PH; and 3) investigate BNP (brain natriuretic peptide) values in infants with BPD-associated PH versus those without BPD-associated PH. This study will allow us to help define a high-risk population at LPCH—namely, premature infants with BPD-associated PH.
| Condition |
|---|
|
Bronchopulmonary Dysplasia (BPD) Pulmonary Hypertension (PH) |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Endothelin-1 (ET-1) and Brain Natriuretic Peptide (BNP) Levels as Predictors of Pulmonary Hypertension Risk in Premature Infants With Bronchopulmonary Dysplasia (BPD) |
Eligibility| Ages Eligible for Study: | up to 30 Weeks |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
LPCH premature neonates
Inclusion Criteria:
- Premature Infants (<30 weeks EGA)
Exclusion Criteria:
- Major congenital malformations (cardiac, respiratory, gastrointestinal)
- congenital infection, and/or
- known genetic syndromes (i.e. trisomy 21)
Contacts and Locations| Contact: Christine Johnson, MD | 650 723-5711 | clcjohns@stanford.edu |
| Contact: Ritue Chitkara, MD | 650 723-5711 | chitkara@stanford.edu |
| United States, California | |
| Lucile Packard Children's Hospital at Stanford | Recruiting |
| Palo Alto, California, United States, 94304 | |
More Information
No publications provided
| Responsible Party: | Stanford University |
| ClinicalTrials.gov Identifier: | NCT01516398 History of Changes |
| Other Study ID Numbers: | BPD22044 |
| Study First Received: | January 19, 2012 |
| Last Updated: | April 4, 2012 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Bronchopulmonary Dysplasia Hypertension Hypertension, Pulmonary Hyperplasia Ventilator-Induced Lung Injury Lung Injury Lung Diseases Respiratory Tract Diseases Infant, Premature, Diseases Infant, Newborn, Diseases |
Vascular Diseases Cardiovascular Diseases Pathologic Processes Natriuretic Peptide, Brain Natriuretic Agents Physiological Effects of Drugs Pharmacologic Actions Cardiovascular Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 16, 2013